Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4904]

FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer

FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer

WCLC 2022: Phase II study of durvalumab plus concurrent radiotherapy in unresectable locally advanced NSCLC: DOLPHIN Study

WCLC 2022: Phase II study of durvalumab plus concurrent radiotherapy in unresectable locally advanced NSCLC:...

WCLC 2022: IASLC Early Detection and Screening Committee report on global obstacles to lung cancer screening in low-to middle-income countries

WCLC 2022: IASLC Early Detection and Screening Committee report on global obstacles to lung cancer screening in...

WCLC 2022: Study of lung cancer gene panel testing demonstrates cytological specimens accurate

WCLC 2022: Study of lung cancer gene panel testing demonstrates cytological specimens accurate

WCLC 2022: Study discloses clinical-relevant intertumoural heterogeneity of NSCLC driven by MET exon 14 skipping

WCLC 2022: Study discloses clinical-relevant intertumoural heterogeneity of NSCLC driven by MET exon 14 skipping

WCLC 2022: National Lung Screening trial finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

WCLC 2022: National Lung Screening trial finds second primary lung cancer is 4 percent and as high as 8 percent...

WCLC 2022: Tumour bulk-RNA sequence identifies NSCLC patients at high risk of progression in non-complete pathological responders from NADIM trial

WCLC 2022: Tumour bulk-RNA sequence identifies NSCLC patients at high risk of progression in non-complete...

WCLC 2022: Sotorasib as a lead-in therapy with pembrolizumab or atezolizumab demonstrates durable clinical activity for advanced KRAS p.G12C NSCLC

WCLC 2022: Sotorasib as a lead-in therapy with pembrolizumab or atezolizumab demonstrates durable clinical...

WCLC 2022: Sugemalimab a safe and effective consolidation therapy for unresectable stage III NSCLC

WCLC 2022: Sugemalimab a safe and effective consolidation therapy for unresectable stage III NSCLC

Protein that may predict future diabetes risk and death from cancer identified

Protein that may predict future diabetes risk and death from cancer identified

More from ecancer